Testing plasma pools for markers of viral contamination: the UK experience.
The transmission of viral infections through the use of products derived from blood has emphasised the need for adequate validation of the production process, testing of materials used in production and quality control tests on the final product. Since the late 1980s, as part of its batch release procedures, NIBSC has tested for markers of viral infectivity plasma pools used in production of blood products used in the UK. As a result of testing over 9,000 pools, NIBSC has identified 9 pools contaminated with HBsAg and 2 pools containing antibodies to HIV-1. Since routine screening of plasma pools for anti-HCV was introduced in 1993, 8 pools out of the 4,000 tested have been found to contain antibodies to HCV. In addition, the release of 12 batches of blood products was withheld and it is known that further batches of material produced from the positive pools were not submitted for batch release. Studies involving assays of dilutions of known positive plasma samples indicated that there is considerable variation in the endpoint dilutions of antigen or antibody detected by test kits from different manufactures. The selection and validation of the kits used in such testing is therefore important. The usefulness of standardised low-level external controls in assays of plasma pools for markers of viral infection is discussed.
Ferguson
M
M
Division of Virology, National Institute for Biological Standards and Control, South Mimms, UK.
Minor
P D
PD
Garrett
A J
AJ
Page
M
M
Thorpe
R
R
Barrowcliffe
T
T
D000914:Antibodies, Viral; D001803:Blood Transfusion / Q000379:methods*; D015658:HIV Infections / Q000175:diagnosis; D015497:HIV-1; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000175:diagnosis; D006525:Hepatitis, Viral, Human / Q000175:diagnosis; D006801:Humans; D014777:Virus Diseases / Q000175:diagnosis*
D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens